Switch to:
Also traded in: Canada

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.06
MSLI's Cash to Debt is ranked lower than
95% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. MSLI: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
MSLI' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 7.60 Max: No Debt
Current: 0.06
Equity to Asset 0.52
MSLI's Equity to Asset is ranked lower than
65% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MSLI: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
MSLI' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.67 Max: 0.94
Current: 0.52
0.18
0.94
Interest Coverage 0.04
MSLI's Interest Coverage is ranked lower than
100% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. MSLI: 0.04 )
Ranked among companies with meaningful Interest Coverage only.
MSLI' s Interest Coverage Range Over the Past 10 Years
Min: 1.01  Med: 23.79 Max: N/A
Current: 0.04
F-Score: 2
Z-Score: 0.39
M-Score: -1.70
WACC vs ROIC
19.93%
-0.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 0.27
MSLI's Operating margin (%) is ranked lower than
74% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. MSLI: 0.27 )
Ranked among companies with meaningful Operating margin (%) only.
MSLI' s Operating margin (%) Range Over the Past 10 Years
Min: -360.47  Med: -14.54 Max: 19.4
Current: 0.27
-360.47
19.4
Net-margin (%) -10.65
MSLI's Net-margin (%) is ranked lower than
80% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. MSLI: -10.65 )
Ranked among companies with meaningful Net-margin (%) only.
MSLI' s Net-margin (%) Range Over the Past 10 Years
Min: -396.76  Med: -37.02 Max: 22.08
Current: -10.65
-396.76
22.08
ROE (%) -3.83
MSLI's ROE (%) is ranked lower than
74% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. MSLI: -3.83 )
Ranked among companies with meaningful ROE (%) only.
MSLI' s ROE (%) Range Over the Past 10 Years
Min: -90.89  Med: -16.19 Max: 5.02
Current: -3.83
-90.89
5.02
ROA (%) -2.42
MSLI's ROA (%) is ranked lower than
73% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. MSLI: -2.42 )
Ranked among companies with meaningful ROA (%) only.
MSLI' s ROA (%) Range Over the Past 10 Years
Min: -48.82  Med: -12.42 Max: 4.57
Current: -2.42
-48.82
4.57
ROC (Joel Greenblatt) (%) 1.61
MSLI's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. MSLI: 1.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MSLI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -621.29  Med: -115.07 Max: 94.35
Current: 1.61
-621.29
94.35
Revenue Growth (3Y)(%) 6.20
MSLI's Revenue Growth (3Y)(%) is ranked higher than
52% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MSLI: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MSLI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.2  Med: -13.70 Max: 44.9
Current: 6.2
-60.2
44.9
EPS Growth (3Y)(%) -85.10
MSLI's EPS Growth (3Y)(%) is ranked lower than
99% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MSLI: -85.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MSLI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.1  Med: -15.70 Max: 65.3
Current: -85.1
-85.1
65.3
» MSLI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

MSLI Guru Trades in Q3 2014

Jim Simons 358,400 sh (-39.04%)
» More
Q4 2014

MSLI Guru Trades in Q4 2014

Jim Simons 328,700 sh (-8.29%)
» More
Q1 2015

MSLI Guru Trades in Q1 2015

Jim Simons 436,200 sh (+32.70%)
» More
Q2 2015

MSLI Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MSLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:CPHR, NAS:AQXP, OTCPK:ELTP, NAS:NEOS, NAS:BPTH, OTCPK:SENZ, NAS:TTPH, NAS:PSDV, NAS:SPHS, NAS:SMMT, NAS:JNP, OTCPK:ORXOY, NAS:EPIX, OTCPK:SCLRF, NAS:AGRX, NAS:CPIX, NAS:ARDM, NAS:LPCN, NAS:ZYNE, AMEX:PVCT » details
Traded in other countries:MSL.Canada,
Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products.

Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Top Ranked Articles about Merus Labs International Inc

Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Commentary and updates on previous recommendations
We are joined this week by contributing editor Ryan Irvine, who gives us his outlook for the markets and updates some previous recommendations. Ryan is the CEO of KeyStone Financial (www.KeyStocks.com) and is one of the country’s top experts in small-cap stocks. He is based in the Vancouver area. Here is his report. Read more...

Ratios

vs
industry
vs
history
Forward P/E 19.46
MSLI's Forward P/E is ranked lower than
62% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. MSLI: 19.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.89
MSLI's P/B is ranked higher than
88% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MSLI: 0.89 )
Ranked among companies with meaningful P/B only.
MSLI' s P/B Range Over the Past 10 Years
Min: 0.29  Med: 0.77 Max: 2.63
Current: 0.89
0.29
2.63
P/S 2.84
MSLI's P/S is ranked lower than
51% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MSLI: 2.84 )
Ranked among companies with meaningful P/S only.
MSLI' s P/S Range Over the Past 10 Years
Min: 0.82  Med: 3.15 Max: 53.85
Current: 2.84
0.82
53.85
POCF 8.03
MSLI's POCF is ranked higher than
85% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. MSLI: 8.03 )
Ranked among companies with meaningful POCF only.
MSLI' s POCF Range Over the Past 10 Years
Min: 1.26  Med: 5.65 Max: 97.22
Current: 8.03
1.26
97.22
EV-to-EBIT 2018.29
MSLI's EV-to-EBIT is ranked lower than
100% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. MSLI: 2018.29 )
Ranked among companies with meaningful EV-to-EBIT only.
MSLI' s EV-to-EBIT Range Over the Past 10 Years
Min: -163.9  Med: 0.60 Max: 2319.1
Current: 2018.29
-163.9
2319.1
EV-to-EBITDA 10.90
MSLI's EV-to-EBITDA is ranked higher than
70% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. MSLI: 10.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
MSLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.7  Med: 0.90 Max: 20.6
Current: 10.9
-155.7
20.6
Current Ratio 0.79
MSLI's Current Ratio is ranked lower than
95% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MSLI: 0.79 )
Ranked among companies with meaningful Current Ratio only.
MSLI' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.57 Max: 14.42
Current: 0.79
0.38
14.42
Quick Ratio 0.61
MSLI's Quick Ratio is ranked lower than
92% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. MSLI: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
MSLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.31  Med: 2.44 Max: 14.42
Current: 0.61
0.31
14.42
Days Inventory 134.86
MSLI's Days Inventory is ranked lower than
62% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. MSLI: 134.86 )
Ranked among companies with meaningful Days Inventory only.
MSLI' s Days Inventory Range Over the Past 10 Years
Min: 153.34  Med: 238.60 Max: 334.61
Current: 134.86
153.34
334.61
Days Sales Outstanding 107.54
MSLI's Days Sales Outstanding is ranked lower than
73% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. MSLI: 107.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.42  Med: 106.05 Max: 325.24
Current: 107.54
0.42
325.24

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.19
MSLI's Price/Projected FCF is ranked higher than
81% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. MSLI: 1.19 )
Ranked among companies with meaningful Price/Projected FCF only.
MSLI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.15  Med: 0.84 Max: 4.05
Current: 1.19
0.15
4.05
Price/Median PS Value 0.89
MSLI's Price/Median PS Value is ranked higher than
73% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. MSLI: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
MSLI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 0.69 Max: 16.67
Current: 0.89
0.02
16.67

More Statistics

Revenue (TTM) (Mil) $46.37
EPS (TTM) $ -0.05
Beta2.51
Short Percentage of Float1.80%
52-Week Range $1.06 - 2.62
Shares Outstanding (Mil)102.60

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Sep16 Sep17 Sep18 Sep19
Revenue (Mil $) 74 94 93 99
EPS ($) -0.01 0.06 0.11 0.19
EPS w/o NRI ($) -0.01 0.06 0.11 0.19
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MSLI

Headlines

Articles On GuruFocus.com
Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Oct 05 2015 
Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc. Jun 22 2015 
Merus Labs International: A Pharma Stock With Growth Potential Mar 30 2015 

More From Other Websites
Merus Labs Appoints Two Senior Executives Jul 04 2016
Merus Announces Reduced Leverage and Provides Business Update Jul 04 2016
Merus Announces Reduced Leverage and Provides Business Update Jul 04 2016
Merus Labs Appoints Two New Senior Executives Jun 30 2016
Merus Labs Appoints Two New Senior Executives Jun 30 2016
Merus Labs International Inc. Announces Deemed Exercise of Special Warrants May 18 2016
Merus Labs International Inc. Announces Deemed Exercise of Special Warrants May 18 2016
Merus Labs reports 2Q loss May 11 2016
Merus Labs reports 2Q loss May 11 2016
Merus Labs Reports Fiscal Q2 2016 Results May 11 2016
Merus Labs Reports Fiscal Q2 2016 Results May 11 2016
March 7, 2016 Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and... Apr 04 2016
Merus Announces Re-Election of Directors Apr 04 2016
Merus announces re-election of directors Mar 30 2016
Merus announces re-election of directors Mar 30 2016
Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from... Mar 07 2016
Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from... Mar 07 2016
Merus Labs International Inc. Announces Closing Of $27 Million Bought Deal Financing Mar 01 2016
Merus Labs International Inc. announces closing of $27 million bought deal financing Mar 01 2016
Merus Announces Inaugural Deal with Sanofi Feb 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)